Recently, the ability of 2DG/ABT263 – ABT737 combinations to induce apoptosis in a xenograft model of prostate cancer was attributed to a disruption of the BAK-MCL1 and BAK-BCL(X)L complex by 2DG and ABT treatments, respectively [53], and hence start to undergo cell death. This evidence concerns the gene BCL2L1 and prostate carcinoma.